Overview

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.
Phase:
Phase 2
Details
Lead Sponsor:
Jacobus Pharmaceutical
Treatments:
3,4-diaminopyridine
4-Aminopyridine
Amifampridine